BridgeBio Pharma may be gearing up for its first approvals, but it’s not taking its foot off the gas in early-stage research. The company inked a pair of R&D deals with the University of Colorado and the Salk Institute—its third and fourth academic collaborations of the year.

One of the first 11 patients to receive CRISPR Therapeutics’ anti-CD19 allogeneic CAR-T cell therapy has died. The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

By employing pain treatment algorithms that vary electrical pulses based on the patient’s movement and target them to the cellular activity within their spinal cord, Medtronic has shown that its implant can deliver strong, sustained pain relief for at least one year compared to conventional neurostimulation therapy.

Things are looking up for Aptinyx, whose stock has been down in the dumps since its lead asset flopped in diabetes-linked pain last year. The company’s post-traumatic stress disorder (PTSD) treatment topped placebo on a composite measure of PTSD symptoms, teeing up an FDA meeting and a pivotal trial next year.

Siteless Californian trial company Science 37 has penned a new deal with Signant Health for digital studies focused on the central nervous system.

3M, maker of the ubiquitous Littmann stethoscope brand, has teamed up with Eko to create a new digital version that aims to amplify sounds and incorporate artificial intelligence listening algorithms.

Abnormalities in the genes p53 and AKT are known to promote the growth and spread of cancer, but the mechanisms behind their destructiveness are not fully understood. A research team led by Moffitt Cancer Center has made a discovery about how the activities of the two altered genes are linked—a revelation they believe could inspire new treatments for breast cancer and other tumor types.

Genentech has tapped an artificial intelligence startup spun out of Stanford University late last year to help it discover new drugs across multiple therapeutic targets.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech, where he will oversee immuno-oncology R&D.

In addition to releasing carbon dioxide, every breath we take exhales a multitude of volatile chemicals from locations throughout the body, not just the lungs. Now, Owlstone Medical has shown that its device can capture these compounds and parse them for signs of liver disease.